July 5 (Bloomberg) -- Octoplus NV won a drug developing and manufacturing contract from an unnamed Danish pharmaceutical company, it said in a statement today.

The contract will make a material contribution to Octoplus’ annual revenues, according to the statement.

Link to Statement:{NSN LNUHZC3PR6RK <GO>}

To contact the editor responsible for this story: Fred Pals at fpals@bloomberg.net